Clinical-stage biopharmaceutical company developing first-in-class small-peptide therapeutics to protect retinal cells and preserve vision in patients with retinal diseases
Clinical-stage biopharmaceutical company developing first-in-class small-peptide therapeutics to protect retinal cells and preserve vision in patients with retinal diseases. Its lead candidate, xelafaslatide (formerly ONL1204), targets Fas-mediated cell death and is being studied in conditions including geographic atrophy associated with dry age-related macular degeneration, retinal detachment, glaucoma, and inherited retinal disease.